5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with clozapine in 1 studies
Studies (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Trials (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Recent Studies (post-2010) (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
---|---|---|---|---|---|
73 | 0 | 8 | 9,691 | 747 | 3,148 |
Protein | Taxonomy | 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide (IC50) | clozapine (IC50) |
---|---|---|---|
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
D | Rattus norvegicus (Norway rat) | 1.066 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
D | Bos taurus (cattle) | 4.09 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Wermuth, CG | 1 |
1 review(s) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and clozapine
Article | Year |
---|---|
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |